Leela Barham and Tim Wilsdon discuss the potential impact that value-based pricing (VBP) may have in the UK and the broader implications for developing international models of Health Technology Assessment (HTA). The article can be found here:
Best practices for grounding brand decision-making in insights
In today’s evolving pharmaceutical landscape, harnessing the power of insights is more critical than ever. Integrating primary, secondary, and analytical...